Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3191234 | 0.92 | TSHR (0.44) | MAPTRXFP1TP53POLBALDH1A1 | |
| SCHEMBL3191182 | 0.89 | MAPT (0.40) | MAPTRXFP1TP53POLBLMNA | |
| SCHEMBL3186132 | 0.85 | MAPT (0.43) | MAPTRXFP1TP53ALDH1A1LMNA | |
| SCHEMBL3178406 | 0.83 | MAPT (0.59) | MAPTRXFP1TP53POLBALDH1A1 | |
| SCHEMBL3186469 | 0.83 | RXFP1 (0.45) | MAPTRXFP1MITFALDH1A1LMNA | |
| SCHEMBL3193908 | 0.83 | HDAC6 (0.41) | MAPTTP53MITFALDH1A1LMNA | |
| SCHEMBL3195522 | 0.83 | MAPT (0.45) | MAPTRXFP1TP53MITFALDH1A1 | |
| SCHEMBL3191696 | 0.83 | MAPT (0.45) | MAPTRXFP1TP53MITFALDH1A1 | |
| SCHEMBL3185759 | 0.83 | MAPT (0.45) | MAPTRXFP1TP53MITFALDH1A1 | |
| SCHEMBL14397670 | 0.80 | MAPT (0.42) | MAPTRXFP1TP53POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671069-B2 | Tricyclic, heteroaromatic compounds modulating CXCR4 and/ or CXCR7 | CHEMOCENTRYX, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20070254915-A1 | CXCR4 MODULATORS | CHEMOCENTRYX, INC. (US) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254915-A1 | CXCR4 MODULATORS | CXCL12, CXCR4, CXCR1 | MAPT 2809/4885RXFP1 1115/4885TP53 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.